المؤلفون: Ascierto, Paolo A, Dummer, Reinhard, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Robert, Caroline, Flaherty, Keith T

المصدر: Ascierto, Paolo A; Dummer, Reinhard; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Robert, Caroline; Flaherty, Keith T (2023). Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology, 41(29):4621-4631.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health, Cancer Research, Oncology

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/238964/7/ZORA238964.pdfTest; info:pmid/37506329; urn:issn:0732-183X

الإتاحة: https://doi.org/10.5167/uzh-238964Test
https://doi.org/10.1200/jco.22.02322Test
https://www.zora.uzh.ch/id/eprint/238964Test/
https://www.zora.uzh.ch/id/eprint/238964/7/ZORA238964.pdfTest

المؤلفون: Tawbi, Hussein A, Robert, Caroline, Brase, Jan C, Gusenleitner, Daniel, Gasal, Eduard, Garrett, James, Savchenko, Alexander, Görgün, Güllü, Flaherty, Keith T, Ribas, Antoni, Dummer, Reinhard, Schadendorf, Dirk, Long, Georgina V, Nathan, Paul D, Ascierto, Paolo A

المصدر: Tawbi, Hussein A; Robert, Caroline; Brase, Jan C; Gusenleitner, Daniel; Gasal, Eduard; Garrett, James; Savchenko, Alexander; Görgün, Güllü; Flaherty, Keith T; Ribas, Antoni; Dummer, Reinhard; Schadendorf, Dirk; Long, Georgina V; Nathan, Paul D; Ascierto, Paolo A (2022). Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with $\textit{BRAF}$V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Journal for ImmunoTherapy of Cancer, 10(6):e004226.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health, Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/220008/1/ZORA_e004226_full.pdfTest; info:pmid/35728875; urn:issn:2051-1426

الإتاحة: https://doi.org/10.5167/uzh-22000810.1136/jitc-2021-004226Test
https://www.zora.uzh.ch/id/eprint/220008Test/
https://www.zora.uzh.ch/id/eprint/220008/1/ZORA_e004226_full.pdfTest

المؤلفون: Dummer, Reinhard, Long, Georgina V, Robert, Caroline, Tawbi, Hussein A, Flaherty, Keith T, Ascierto, Paolo A, Nathan, Paul D, Rutkowski, Piotr, Leonov, Oleg, Dutriaux, Caroline, Mandalà, Mario, Lorigan, Paul, Ferrucci, Pier Francesco, Grob, Jean Jacques, Meyer, Nicolas, Gogas, Helen, Stroyakovskiy, Daniil, Arance, Ana, Brase, Jan C, Green, Steven, Haas, Tomas, Masood, Aisha, Gasal, Eduard, Ribas, Antoni, Schadendorf, Dirk

المصدر: Dummer, Reinhard; Long, Georgina V; Robert, Caroline; Tawbi, Hussein A; Flaherty, Keith T; Ascierto, Paolo A; Nathan, Paul D; Rutkowski, Piotr; Leonov, Oleg; Dutriaux, Caroline; Mandalà, Mario; Lorigan, Paul; Ferrucci, Pier Francesco; Grob, Jean Jacques; Meyer, Nicolas; Gogas, Helen; Stroyakovskiy, Daniil; Arance, Ana; Brase, Jan C; Green, Steven; Haas, Tomas; Masood, Aisha; Gasal, Eduard; Ribas, Antoni; Schadendorf, Dirk (2022). Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 40(13):1428-1438.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health, Cancer Research, Oncology

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/213526/1/928_Dummer_R._et_al._Randomized_Phase_III_Trial_Evaluationg_Spartalizumab_plus_Dabrafenib_and_Trametinib_for_BRAF_V600_mutant_JCO_2022.pdfTest; info:pmid/35030011; urn:issn:0732-183X

الإتاحة: https://doi.org/10.5167/uzh-21352610.1200/jco.21.01601Test
https://www.zora.uzh.ch/id/eprint/213526Test/
https://www.zora.uzh.ch/id/eprint/213526/1/928_Dummer_R._et_al._Randomized_Phase_III_Trial_Evaluationg_Spartalizumab_plus_Dabrafenib_and_Trametinib_for_BRAF_V600_mutant_JCO_2022.pdfTest

المؤلفون: Schadendorf, Dirk, Robert, Caroline, Dummer, Reinhard, Flaherty, Keith T, Tawbi, Hussein A, Menzies, Alexander M, Banerjee, Hiya, Lau, Mike, Long, Georgina V

المصدر: Schadendorf, Dirk; Robert, Caroline; Dummer, Reinhard; Flaherty, Keith T; Tawbi, Hussein A; Menzies, Alexander M; Banerjee, Hiya; Lau, Mike; Long, Georgina V (2021). Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer, 153:234-241.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health, Cancer Research, Oncology

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/206022/1/903_Schadendorf_D._et_al._Pyrexia_in_patients_treated_with_dabrafenib_plus_trametinib_across_clinical_trials_in_BRAF-mutant_cancers_EJC_2021.pdfTest; info:pmid/34225229; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-20602210.1016/j.ejca.2021.05.005Test
https://www.zora.uzh.ch/id/eprint/206022Test/
https://www.zora.uzh.ch/id/eprint/206022/1/903_Schadendorf_D._et_al._Pyrexia_in_patients_treated_with_dabrafenib_plus_trametinib_across_clinical_trials_in_BRAF-mutant_cancers_EJC_2021.pdfTest

المؤلفون: Ascierto, Paolo A, Dummer, Reinhard, Gogas, Helen J, Flaherty, Keith T, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, Jan Willem B, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D, Robert, Caroline

المصدر: Ascierto, Paolo A; Dummer, Reinhard; Gogas, Helen J; Flaherty, Keith T; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; de Groot, Jan Willem B; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. European Journal of Cancer, 126:33-44.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/183844/8/1-s2.0-S095980491930841X-main.pdfTest; info:pmid/31901705; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-18384410.1016/j.ejca.2019.11.016Test
https://www.zora.uzh.ch/id/eprint/183844Test/
https://www.zora.uzh.ch/id/eprint/183844/8/1-s2.0-S095980491930841X-main.pdfTest

المؤلفون: Gogas, Helen J, Flaherty, Keith T, Dummer, Reinhard, Ascierto, Paolo A, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Vanna Chiarion, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Gollerkeri, Ashwin, Pickard, Michael D, Robert, Caroline

المصدر: Gogas, Helen J; Flaherty, Keith T; Dummer, Reinhard; Ascierto, Paolo A; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Sileni, Vanna Chiarion; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Gollerkeri, Ashwin; Pickard, Michael D; Robert, Caroline (2019). Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer, 119:97-106.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/174049/1/809_Gogas_H._et_al._Adverse_events_associated_with_encorafenib_plus_binimetinib_in_the_COLUMBUS_study_EJC_2019.pdfTest; info:pmid/31437754; urn:issn:0959-8049

الإتاحة: https://doi.org/10.5167/uzh-17404910.1016/j.ejca.2019.07.016Test
https://www.zora.uzh.ch/id/eprint/174049Test/
https://www.zora.uzh.ch/id/eprint/174049/1/809_Gogas_H._et_al._Adverse_events_associated_with_encorafenib_plus_binimetinib_in_the_COLUMBUS_study_EJC_2019.pdfTest

المؤلفون: Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux, Caroline, de Groot, Jan Willem B, Yamazaki, Naoya, Loquai, Carmen, Moutouh-de Parseval, Laure A, Pickard, Michael D, Sandor, Victor, Robert, Caroline, Flaherty, Keith T

المصدر: Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 19(5):603-615.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/151962/1/747_Dummer_R._et_al._Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_Lancet_Oncology_2018.pdfTest; https://www.zora.uzh.ch/id/eprint/151962/8/Dummer_et_al_Lancet_Oncology_13.12.17.pdfTest; info:pmid/29573941; urn:issn:1470-2045

الإتاحة: https://doi.org/10.5167/uzh-15196210.1016/S1470-2045Test(18)30142-6
https://www.zora.uzh.ch/id/eprint/151962Test/
https://www.zora.uzh.ch/id/eprint/151962/1/747_Dummer_R._et_al._Encorafenib_plus_binimetinib_versus_vemurafenib_or_encorafenib_in_patients_Lancet_Oncology_2018.pdfTest
https://www.zora.uzh.ch/id/eprint/151962/8/Dummer_et_al_Lancet_Oncology_13.12.17.pdfTest

المؤلفون: Izar, Benjamin, Sharfman, William, Hodi, F Stephen, Lawrence, Donald, Flaherty, Keith T, Amaravadi, Ravi, Kim, Kevin B, Puzanov, Igor, Sosman, Jeffrey, Dummer, Reinhard, Goldinger, Simone M, Lam, Lyhping, Kakar, Shefali, Tang, Zhongwen, Krieter, Oliver, McDermott, David F, Atkins, Michael B

المصدر: Izar, Benjamin; Sharfman, William; Hodi, F Stephen; Lawrence, Donald; Flaherty, Keith T; Amaravadi, Ravi; Kim, Kevin B; Puzanov, Igor; Sosman, Jeffrey; Dummer, Reinhard; Goldinger, Simone M; Lam, Lyhping; Kakar, Shefali; Tang, Zhongwen; Krieter, Oliver; McDermott, David F; Atkins, Michael B (2017). A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine, 6(8):1904-1914.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/139265/1/707_Izar_B._et_al._A_first-in-human_phase_I,_multicenter,_open-label,_dose-escalation_study_of_the_oral_Cancer_Med_2017.pdfTest; info:pmid/28719152; urn:issn:2045-7634

الإتاحة: https://doi.org/10.5167/uzh-13926510.1002/cam4.1140Test
https://www.zora.uzh.ch/id/eprint/139265Test/
https://www.zora.uzh.ch/id/eprint/139265/1/707_Izar_B._et_al._A_first-in-human_phase_I,_multicenter,_open-label,_dose-escalation_study_of_the_oral_Cancer_Med_2017.pdfTest

المؤلفون: Smith, Michael P, Rowling, Emily J, Miskolczi, Zsofia, Ferguson, Jennifer, Spoerri, Loredana, Haass, Nikolas K, Sloss, Olivia, McEntegart, Sophie, Arozarena, Imanol, von Kriegsheim, Alex, Rodriguez, Javier, Brunton, Holly, Kmarashev, Jivko, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Andrews, Miles C, Cooper, Zachary A, Flaherty, Keith T, Wargo, Jennifer A, Wellbrock, Claudia

المصدر: Smith, Michael P; Rowling, Emily J; Miskolczi, Zsofia; Ferguson, Jennifer; Spoerri, Loredana; Haass, Nikolas K; Sloss, Olivia; McEntegart, Sophie; Arozarena, Imanol; von Kriegsheim, Alex; Rodriguez, Javier; Brunton, Holly; Kmarashev, Jivko; Levesque, Mitchell P; Dummer, Reinhard; Frederick, Dennie T; Andrews, Miles C; Cooper, Zachary A; Flaherty, Keith T; Wargo, Jennifer A; Wellbrock, Claudia (2017). Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Molecular Medicine, 9(8):1011-1029.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/139241/1/706_Smith_MP._et_al._Targeting_endothelin_receptor_signalling_overcomes_heterogeneity_driven_therapy_failure_EMBO_Mol_Med._2017.pdfTest; info:pmid/28606996; urn:issn:1757-4676

الإتاحة: https://doi.org/10.5167/uzh-13924110.15252/emmm.201607156Test
https://www.zora.uzh.ch/id/eprint/139241Test/
https://www.zora.uzh.ch/id/eprint/139241/1/706_Smith_MP._et_al._Targeting_endothelin_receptor_signalling_overcomes_heterogeneity_driven_therapy_failure_EMBO_Mol_Med._2017.pdfTest

المؤلفون: Smith, Michael P, Brunton, Holly, Rowling, Emily J, Ferguson, Jennifer, Arozarena, Imanol, Miskolczi, Zsofia, Lee, Jessica L, Girotti, Maria R, Marais, Richard, Levesque, Mitchell P, Dummer, Reinhard, Frederick, Dennie T, Flaherty, Keith T, Cooper, Zachary A, Wargo, Jennifer A, Wellbrock, Claudia

المصدر: Smith, Michael P; Brunton, Holly; Rowling, Emily J; Ferguson, Jennifer; Arozarena, Imanol; Miskolczi, Zsofia; Lee, Jessica L; Girotti, Maria R; Marais, Richard; Levesque, Mitchell P; Dummer, Reinhard; Frederick, Dennie T; Flaherty, Keith T; Cooper, Zachary A; Wargo, Jennifer A; Wellbrock, Claudia (2016). Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell, 29(3):270-84.

مصطلحات موضوعية: Dermatology Clinic, 610 Medicine & health

وصف الملف: application/pdf

العلاقة: https://www.zora.uzh.ch/id/eprint/123665/1/645_Smith%20MP%20et%20al._Inhibiting%20Drivers%20of%20Non-mutational%20Drug%20Tolerance_Cancer%20Cell%202016.pdfTest; info:pmid/26977879; urn:issn:1535-6108

الإتاحة: https://doi.org/10.5167/uzh-12366510.1016/j.ccell.2016.02.003Test
https://www.zora.uzh.ch/id/eprint/123665Test/
https://www.zora.uzh.ch/id/eprint/123665/1/645_Smith%20MP%20et%20al._Inhibiting%20Drivers%20of%20Non-mutational%20Drug%20Tolerance_Cancer%20Cell%202016.pdfTest